Research Article

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results

Table 2

Outcomes after switching to aflibercept in patients with neovascular AMD.

All (, year 1; 118, year 2; 58, year 3)Group 1 bevacizumab (, year 1; 66, year 2; 22, year 3)Group 2 ranibizumab (, year 1; 52, year 2; 36, year 3)

BCVA, ETDRS score
 Before switch56.5 ± 15.756.5 ± 16.856.3 ± 13.9
 After 1 year54.6 ± 19.00.02754.8 ± 19.80.10854.3 ± 17.90.127
 After 2 years54.6 ± 16.70.00157.3 ± 16.20.16351.2 ± 16.90.001
 After 3 years50.3 ± 19.1<0.00150.8 ± 22.30.01650.1 ± 17.20.001
CRT, μm
 Before switch386.2 ± 163.7406.7 ± 184.4370.7 ± 163.8
 After 1 year313.2 ± 140.9<0.001329.7 ± 152.6<0.001287.5 ± 116.8<0.001
 After 2 years280.2 ± 121.3<0.001270.0 ± 107.3<0.001293.1 ± 137.1<0.001
 After 3 years266.1 ± 123.5<0.001259.4 ± 85.7<0.001269.7 ± 140.9<0.001
Injections per year, n
 In the first year7.8 ± 2.68.0 ± 2.67.8 ± 2.1
 In the second year6.8 ± 3.50.0077.5 ± 3.50.2196.1 ± 3.2<0.001
 In the third year6.5 ± 3.10.0027.3 ± 2.815.9 ± 3.1<0.001

Outcomes are expressed as mean values ± SD.